Patisiran

Drug Overview

In the specialized field of hematology and genetic medicine, managing protein-related disorders requires high-precision tools. Patisiran is a groundbreaking medication that belongs to a modern drug class known as siRNA (small interfering RNA). This therapy represents a major leap in medical science, as it does not just treat the symptoms of a disease but works to “silence” the specific genetic instructions that cause the disease in the first place.

Within the TARGETED THERAPY landscape, patisiran is designed to address a rare and serious condition called Hereditary Transthyretin-mediated (hATTR) amyloidosis. This condition involves the buildup of abnormal proteins in the body’s tissues, which can lead to severe nerve and organ damage. By intervening at the genetic level, patisiran helps prevent the liver from producing the harmful proteins that drive this process.

• Generic Name: Patisiran
• US Brand Name: Onpattro
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Fully FDA-approved for the treatment of the polyneuropathy (nerve damage) caused by hATTR amyloidosis in adults.

What Is It and How Does It Work? (Mechanism of Action)

To understand how patisiran works, it is helpful to look at how our bodies build proteins. Our cells use a “blueprint” called messenger RNA (mRNA) to tell our organs which proteins to make. In hATTR amyloidosis, the liver receives a faulty blueprint to produce a protein called transthyretin (TTR). This faulty TTR protein misfolds and clumps together, forming “amyloid deposits” in the nerves, heart, and digestive tract.

Patisiran is an advanced BIOLOGIC and TARGETED THERAPY that uses a process called RNA interference (RNAi). It consists of small pieces of double-stranded RNA encapsulated in a lipid nanoparticle—a tiny fat bubble that helps the drug travel safely to the liver.

At the molecular and hematological level, the mechanism involves the following steps:

1. Liver Targeting: Once infused, the lipid nanoparticles are naturally drawn to the liver, which is the primary factory for TTR protein.
2. mRNA Silencing: Inside the liver cells, patisiran identifies and attaches to the specific mRNA “blueprint” for the TTR protein.
3. Protein Reduction: By binding to this blueprint, patisiran triggers a natural cellular process that destroys the mRNA before it can be used to build a protein.
4. Circulation Clearance: Because the “instructions” are destroyed, the liver produces significantly less TTR protein. This leads to a massive drop in the levels of TTR circulating in the blood, which reduces the formation of new amyloid deposits and may help the body manage existing ones.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for patisiran is the treatment of the polyneuropathy of Hereditary Transthyretin-mediated (hATTR) amyloidosis in adults. Polyneuropathy refers to widespread nerve damage that causes symptoms like numbness, tingling, burning pain, and severe muscle weakness. This condition is progressive, meaning it worsens over time without intervention. Patisiran is used in the hematology and neurology drug categories to slow the progression of these nerve symptoms and improve the patient’s quality of life.

Other Approved & Off-Label Uses

While the primary label focuses on nerve damage, the medical community continues to monitor its effects on other systems:

• Cardiomyopathy Support: Although it is specifically approved for nerve damage, many patients with hATTR also have heart involvement (amyloidosis in the heart muscle). Physicians often monitor heart function in patients receiving patisiran for polyneuropathy.
• Wild-Type ATTR: Research has been conducted into the use of TTR-silencers for non-hereditary (wild-type) amyloidosis, though patisiran’s current FDA-approved label remains specific to the hereditary form.

Dosage and Administration Protocols

Patisiran is administered as an intravenous infusion by a healthcare professional, typically in a clinical setting or infusion center.

Important Adjustments:

• Pre-medication: To prevent infusion-related reactions, patients must receive specific medications at least 60 minutes before the infusion starts. These typically include an IV corticosteroid (dexamethasone), oral paracetamol (acetaminophen), and IV antihistamines (H1 and H2 blockers).
• Renal/Hepatic Insufficiency: Clinical data suggests that no dose adjustment is required for patients with mild to moderate kidney or liver impairment.
• Missed Doses: If a dose is missed, it should be administered as soon as possible. If the next scheduled dose is less than 3 days away, the missed dose is usually skipped to maintain the 3-week cycle.

Clinical Efficacy and Research Results

Current clinical study data from the 2020-2026 period confirms the sustained efficacy of patisiran. The landmark APOLLO trial was the first to demonstrate that patisiran could actually improve, rather than just slow down, nerve damage in some patients.

Numerical data from long-term extension studies showed:

• TTR Reduction: Patients achieved a median reduction in serum TTR levels of approximately 81% to 84%.
• Nerve Function: Over 18 months, many patients experienced an improvement in their mNIS+7 score (a test measuring nerve strength and sensation) compared to those receiving a placebo.
• Walking Ability: A significant number of patients maintained or improved their walking speed and physical activity levels over several years of treatment.

Recent research (2025-2026) focusing on the hematological clearance of amyloid-forming proteins continues to support patisiran as a gold standard in TARGETED THERAPY for this patient population.

Safety Profile and Side Effects

Black Box Warning

Patisiran does not currently have an FDA “Black Box Warning.”

Common side effects (>10%)

• Upper Respiratory Tract Infections: Such as the common cold, sore throat, or nasal congestion.
• Infusion-Related Reactions (IRRs): Symptoms like flushing, back pain, nausea, abdominal pain, or headache during the infusion.
• Peripheral Edema: Swelling in the arms, legs, or ankles.

Serious adverse events

• Vitamin A Deficiency: Because TTR protein is responsible for transporting Vitamin A in the blood, silencing the protein causes Vitamin A levels to drop.
• Severe Infusion Reactions: In rare cases, patients may experience difficulty breathing, chest pain, or low blood pressure during treatment.
• Ocular Symptoms: Potential for dry eyes or night blindness due to low Vitamin A.

Management Strategies

Infusion reactions are managed by slowing or stopping the infusion and providing additional medical support. To manage the decrease in Vitamin A, all patients are required to take a daily Vitamin A supplement. If patients develop vision changes, they must be referred to an ophthalmologist immediately.

Research Areas

In 2026, research is moving toward even more convenient delivery systems and broader applications for siRNA technology. Active clinical trials are investigating the long-term impact of TTR-silencing on heart tissue (regression of amyloid). Additionally, newer medications in this class (like vutrisiran) have been developed to allow for subcutaneous (under the skin) injections rather than IV infusions. The hematology community is also exploring how silencing proteins can be used to treat other systemic diseases where the liver produces “toxic” or misfolded proteins.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

Before starting patisiran, healthcare providers will order several baseline tests:

• Vitamin A Levels: To establish a baseline before supplementation begins.
• Liver Function Tests (LFTs): To ensure the liver can process the medication.
• Kidney Function Tests: To assess overall health and clearance.
• Neurological Exam: To document the current level of nerve damage (mNIS+7 baseline).

Precautions during treatment

• Infusion Monitoring: Patients should be watched closely during the 80-minute infusion for any signs of IRRs.
• Eye Exams: Regular check-ups with an eye doctor are recommended to monitor for signs of Vitamin A deficiency.
• Vigilance for Edema: Patients should report sudden weight gain or swelling in the legs to their physician.

“Do’s and Don’ts” List

• DO take your daily Vitamin A supplement exactly as prescribed by your doctor.
• DO ensure you receive all pre-medications (steroids/antihistamines) before every infusion.
• DO report any “night blindness” or difficulty seeing in low light to your medical team.
• DON’T take extra Vitamin A beyond what is prescribed, as this will not increase your blood levels and can be harmful.
• DON’T skip scheduled infusions; the success of this TARGETED THERAPY depends on keeping TTR levels consistently low.
• DON’T ignore signs of flushing or back pain during the infusion—tell the nurse immediately.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Hereditary ATTR amyloidosis is a complex condition that requires ongoing management by a specialist medical team. Always consult your physician regarding diagnosis, treatment options, and any side effects experienced during therapy.